›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Invitae Common Hereditary Cancers Panel
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Invitae CorpType:
FDA Approved
Related tests:
The Invitae Common Hereditary Cancers panel analyzes 47 genes associated with hereditary breast, ovarian, uterine, prostate, colorectal, gastric, melanoma, and pancreatic cancers. Individuals with a pathogenic variant in one of these genes have an increased risk of developing certain cancers, many of which may be difficult both to detect and to treat. Identifying those at high risk enables implementation of additional screening, surveillance, and interventions. These efforts may result in risk reduction and early diagnosis, increasing the chances of successful treatment and survival.
Cancer:
Breast Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Uterine Cancer
Gene:
APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), AXIN2 (Axin 2), BARD1 (BRCA1 Associated RING Domain 1), BMPR1A (Bone Morphogenetic Protein Receptor Type 1A), BRCA1 (Breast cancer 1, early onset)
See More ...
APC (APC Regulator Of WNT Signaling Pathway), ATM (ATM serine/threonine kinase), AXIN2 (Axin 2), BARD1 (BRCA1 Associated RING Domain 1), BMPR1A (Bone Morphogenetic Protein Receptor Type 1A), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1), CDK4 (Cyclin-dependent kinase 4), CDKN1A (Cyclin-dependent kinase inhibitor 1A), CHEK2 (Checkpoint kinase 2), CTNNA1 (Catenin Alpha 1), DICER1 (Dicer 1 Ribonuclease III), EPCAM (Epithelial cell adhesion molecule), GREM1 (Gremlin 1), HOXB13 (Homeobox B13), KIT (KIT proto-oncogene, receptor tyrosine kinase), MEN1 (Menin 1), MLH1 (MutL homolog 1), MSH2 (MutS Homolog 2), MSH3 (MutS Homolog 3), MSH6 (MutS homolog 6), MUTYH (MutY homolog), NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)), NF1 (Neurofibromin 1), PALB2 (Partner and localizer of BRCA2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), PMS2 (PMS1 protein homolog 2), POLD1 (DNA Polymerase Delta 1), POLE (DNA Polymerase Epsilon), PTEN (Phosphatase and tensin homolog), RAD50 (RAD50 Double Strand Break Repair Protein), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A), SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), SDHC (Succinate Dehydrogenase Complex Subunit C), SDHD (Succinate Dehydrogenase Complex Subunit D), SMAD4 (SMAD family member 4), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53), TSC1 (TSC complex subunit 1), TSC2 (TSC complex subunit 2), VHL (von Hippel-Lindau tumor suppressor)
Method:
Next-Generation Sequencing (NGS)
